Welcome to our dedicated page for Regentis Biomaterials SEC filings (Ticker: RGNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Regentis Biomaterials Ltd. (RGNT) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and registration materials related to its NYSE American listing. As a foreign private issuer, Regentis uses Form 6-K to furnish press releases and other information that it makes public in its home market or files with other regulators.
Recent 6-K filings incorporate press releases on clinical and scientific developments for GelrinC, the company’s lead cell-free, off-the-shelf hydrogel implant for focal articular knee cartilage injuries. For example, a 6-K furnishes the press release titled “Regentis’ GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation,” summarizing Phase II data published in the journal Cartilage and describing MRI-based MOCART scores at 24 months. Another 6-K includes the press release “Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC,” outlining patent protection for the liquid, ready-to-use formulation and solvent-free production processes.
Filings also cover corporate and governance events, such as changes in executive leadership, and provide formal notice of these developments under the Exchange Act. In addition, the company’s registration statement on Form F-1 and related documents detail its initial public offering of ordinary shares and listing on the NYSE American under the symbol RGNT.
On Stock Titan, these SEC documents are updated as they are made available through EDGAR. AI-powered tools can help readers quickly understand the key points in each filing, such as clinical endpoints, regulatory milestones, intellectual property disclosures, and changes in management, without needing to parse every page manually.
Regentis Biomaterials Ltd., a foreign private issuer based in Israel, reports that it has requested withdrawal of its Registration Statement No. 333-295510 on Form F-1, effective June 15, 2026. The company has decided not to pursue the public offering that was planned under this registration.
Regentis Biomaterials Ltd. filed Amendment No. 1 to its Form F-1 (Registration No. 333-295510) to file an updated Exhibit 23.1 and to amend and restate the Exhibit Index in Part II. The amendment expressly omits prospectus changes in Part I and does not change the offering terms disclosed earlier.
The filing also discloses prior unregistered financings and convertible loans, including aggregate convertible financings of $900,000 (2020 CLAs) and $835,000 (2021 CLAs), conversions into Ordinary Shares, multiple bridge loans and CEO loan arrangements with interest at 8% and related warrants. Signature pages and U.S. authorized representative attestations are included.
Regentis Biomaterials Ltd. plans to begin European surgeon training for its GelrinC knee cartilage repair implant in the third quarter of 2026, advancing preparations for commercial rollout in Europe, where the product holds CE Mark approval. Initial hands-on training will occur at Humanitas Research Hospital in Milan, with additional sessions across other European markets. The company is building a network of European Centers of Excellence to support surgeon education, clinical guidance, and knowledge sharing around GelrinC. GelrinC is an off-the-shelf, cell-free hydrogel implant with a roughly 10-minute, single-step procedure, positioned as an alternative to microfracture and complex cell-based therapies. Regentis is targeting an estimated $3 billion U.S. market of about 470,000 annual knee cartilage repair cases, and GelrinC is also being evaluated in a pivotal FDA study that has completed more than 50% of enrollment.
Regentis Biomaterials Ltd. filed an amended Form 6-K to update materials for its Annual General Meeting on July 2, 2026. Shareholders will vote on re-electing Class I directors, ratifying external directors Pini Ben Elazar and Susan Alpert, and adopting a new compensation policy.
The agenda also includes multiple equity awards: options for directors and external directors, including 24,826 options per recipient at an exercise price of $2.16 per share, an 8,313-option top-up grant to Pini Ben-Elazar at NIS 0.01, and warrants to purchase 31,250 and 12,500 ordinary shares for Ehud Geller and Jeff Dykan at NIS 0.01 per share. Shareholders will vote on reappointing Deloitte Israel & Co. as auditor and reviewing 2025 financial statements. As of May 26, 2026, 5,179,378 ordinary shares were issued and outstanding.
Regentis Biomaterials Ltd. has called its Annual General Meeting for July 2, 2026 at 3:00 p.m. Israel time in Tel Aviv. Shareholders as of the June 9, 2026 record date will vote on re-electing two Class I directors, adopting a new compensation policy, and re-appointing Deloitte Israel as auditor for 2026.
The agenda includes equity-based pay items: option grants of 24,826 options each to three non-executive directors at an exercise price of US$2.16, a fully vested top-up grant of 8,313 options to director Pini Ben-Elazar at NIS 0.01, and replacement warrants to purchase 31,250 and 12,500 ordinary shares for related-party lenders at NIS 0.01 per share. The board unanimously recommends voting in favor of all proposals.
Regentis Biomaterials Ltd. is registering 3,333,334 Ordinary Shares in a firm commitment offering at an assumed public offering price of $3.00 per share. The underwriters have a 45-day option for 500,000 additional Ordinary Shares (15% of the offering) to cover over-allotments.
The company is an emerging growth company and foreign private issuer listed on NYSE American under the symbol RGNT. The prospectus describes GelrinC (CE-marked in Europe), ongoing pivotal IDE trial enrollment (47 of 80 patients treated; 43 completed two-year follow-up), a patent portfolio (27 granted, 4 pending), recent collaboration with Humanitas Hospital, and recent management changes.
REGENTIS BIOMATERIALS LTD. Chief Medical Officer Galit Reske reported initial holdings of an employee stock option to buy 67,961 shares of common stock. The option has a $4.00 exercise price and expires on February 23, 2037.
The option was granted on February 23, 2026 and vests over three years. One-sixth of the option vests six months after the grant date, and one-twelfth vests on the last day of each subsequent three-month period, subject to continued employment.
REGENTIS BIOMATERIALS LTD. director and Chief Executive Officer Ehud Geller filed an initial Form 3 detailing his derivative holdings in the company. He reports fully vested employee stock options to acquire 182,000 shares of common stock at an exercise price of $0.01 per share, expiring on December 5, 2035, and additional fully vested options over 283,533 shares at the same exercise price, expiring on March 20, 2035. He also reports directly held warrants that are currently exercisable to purchase 92,821 ordinary shares at an exercise price of $5.00 per share, with a three-year term ending on December 5, 2028. The filing records these derivative positions but does not report any new purchases or sales.
REGENTIS BIOMATERIALS LTD. filed an initial insider ownership report for board member Susan Alpert, PHD MD. The Form 3 identifies her as a director of the company but does not list any equity transactions or changes in holdings at this time.